What’s New at SST Corporation
Shilpa Medicare Limited successfully underwent a 2-day inspection by The French Health Products Safety Agency (Afssaps), ending on March 10, 2010. The Oncology manufacturing site located at Deosugur Industrial Area was considered to be in full compliance with the principles of Good Manufacturing Practice (EU GMP Part II) for the active substance Gemcitabine Hydrochloride. This outcome marks another milestone in compliance, reflecting Shilpa Medicare Limited’s continued commitment to supplying high-quality pharmaceutical active ingredients to the highly regulated markets of the European Union.
Erregierre successfully underwent a 4-day US FDA inspection, ending on May 20, 2010. Manufacturing sites in San Paolo d'Argon and Sovere were both judged in full compliance with quality and regulatory requirements and no 483 forms were released by the inspector. This result confirms, once again, the high level of compliance that represents one of the key assets of Erregierre, which is committed to supplying a wide range of pharmaceutical active ingredients to the worldwide pharmaceutical industry.
Read the full story.
Please contact us to arrange a meeting with one of our representatives.
Patented products available for R&D use as permitted under 35 USC ¶ 271 (e) (1).

October 2009
May 2009
March 2009
February 2008
January 2008
September 2007
March 2007
January 2007
Winter 2006
Spring 2006 